Nicholas John Palmer

This inventor holds 15 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignee: Astrazeneca Ab. Active years: 2016-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nicholas John Palmer. Retrieved from https://idiyas.com/inventor/nicholas-john-palmer

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15 (Patent Applications = 4)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 7)

Average Co-Inventor Count = 12.0

ph-index = 6

Forward Citations = 134(Granted Patents)

Company Filing History:

15 out of 1,531

Astrazeneca Ab

patents

Years Active: 2016-2024

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12054465 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2024-08-06),

2. 11814359 - Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2023-11-14),

3. 11773069 - Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2023-10-03),

4. 11680049 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2023-06-20),

5. 11673872 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2023-06-13),

6. 11673871 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2023-06-13),

7. 11667615 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2023-06-06),

8. 11655224 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2023-05-23),

9. 11655223 - Certain (2S)-N-[(1 s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2023-05-23),

10. 11655222 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2023-05-23),

11. 11655221 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2023-05-23),

12. 11117874 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2021-09-14),

13. 10669245 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides dipeptidyl peptidase 1 inhibitors (2020-06-02),

14. 10287258 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2019-05-14),

15. 9522894 - [object Object] (2016-12-20),

Title: Innovations of Nicholas John Palmer

Introduction

Nicholas John Palmer is a notable inventor based in Cheshire, GB. He has made significant contributions to the field of pharmaceuticals, holding a total of 15 patents. His work primarily focuses on developing compounds that have therapeutic applications.

Latest Patents

Among his latest patents are certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides, which serve as dipeptidyl peptidase 1 inhibitors. These compounds are designed to inhibit dipeptidyl peptidase 1 (DPP1) activity, which is crucial in treating and preventing clinical conditions such as respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD). The patents also cover their utility in therapy, pharmaceutical compositions containing them, and processes for preparing such compounds.

Career Highlights

Nicholas John Palmer is currently associated with AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca has allowed him to contribute to innovative solutions in healthcare, particularly in the development of new therapeutic agents.

Collaborations

He has collaborated with notable colleagues, including Stephen Connolly and Steven Swallow, to advance research and development in his field.

Conclusion

Nicholas John Palmer's contributions to pharmaceutical innovations and his extensive patent portfolio highlight his role as a significant inventor in the industry. His work continues to impact the treatment of respiratory diseases and showcases the importance of innovation in healthcare.

Profile summary based on public USPTO records.